Sanofi Reports P-III (ATLAS-INH) and (ATLAS A/B) Studies Results of Fitusiran for the Treatment of Hemophilia A or B
Shots:
- The P-III study (ATLAS-INH) published in the Lancet & (ATLAS A/B) study published in the Lancet Haematology evaluating the safety and efficacy of fitusiran (80mg, SC, qm) in a ratio (2:1) in 57 and 120 males aged ≥12 yrs. with sev. hemophilia A or B
- In the studies (ATLAS-INH) & (ATLAS A/B), 66% of patients with inhibitors & 51% without inhibitors treated with fitusiran (siRNA therapy) experienced zero bleeding episodes vs 5% & 5% with the on-demand bypassing agent after 9mos. of treatment & clotting factor concentrates, respectively
- Both studies met its 1EPS & 2EPs & showed that prophylactic treatment with fitusiran reduced annualized bleeding rates by 90%, improvement in bleeding episodes over on-demand treatments & QoL
Ref: two fitusiran | Image: two fitusiran
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
